Supernus Shareholder Rights Firm Investigates Indivior Acquisition
Event summary
- Halper Sadeh LLC is investigating the sale of Supernus Pharmaceuticals to Indivior Pharmaceuticals for 1.5401 Indivior shares per Supernus share.
- The law firm alleges potential violations of federal securities laws and breaches of fiduciary duties by Supernus' board.
- Concerns include whether Supernus obtained the best possible price and conducted a fair sales process.
- Halper Sadeh may seek increased consideration or additional disclosures on behalf of shareholders.
The big picture
The investigation highlights ongoing tensions between pharmaceutical acquisitions and shareholder value. With Indivior's focus on opioid addiction treatments and Supernus' portfolio of neurological and psychiatric drugs, the deal could reshape the mental health treatment landscape. The outcome of this investigation may set a precedent for future pharmaceutical M&A governance standards.
What we're watching
- Deal Valuation
- Whether the 1.5401 share exchange ratio represents fair value for Supernus shareholders.
- Regulatory Scrutiny
- The level of regulatory oversight the acquisition may attract given the legal investigation.
- Shareholder Activism
- The likelihood of increased shareholder activism if the investigation uncovers significant governance concerns.
Related topics